How Lunsumio Targets Lymphoma Cells
Lunsumio (mosunetuzumab) is a bispecific T-cell engager antibody approved for relapsed or refractory follicular lymphoma after at least two prior therapies. It binds CD20 on B-cell lymphoma cells and CD3 on T cells, redirecting T cells to kill cancer cells via immune activation.[1]
Step-by-Step Mechanism of Action
1. Binding Phase: One arm of Lunsumio attaches to CD20, a protein overexpressed on malignant B cells in follicular lymphoma. The other arm binds CD3 on cytotoxic T cells.
2. T-Cell Recruitment: This bridge clusters T cells near lymphoma cells, forming an immunological synapse.
3. Cytotoxic Response: T cells release perforin and granzymes, inducing lymphoma cell apoptosis. Cytokine release amplifies the response, though step-up dosing minimizes cytokine release syndrome (CRS).[1][2]
Unlike CAR-T therapies, Lunsumio is off-the-shelf, avoiding manufacturing delays.
Treatment Schedule and Dosing
Administered intravenously in 21-day cycles, up to 8 cycles for responders:
- Cycle 1: Day 1 (1 mg), Day 8 (2 mg), Day 15 (60 mg).
- Cycles 2-8: Day 1 (60 mg).
Premedication with steroids, antihistamines, and anti-pyretics reduces CRS risk. Median response duration exceeds 22 months in trials.[1][3]
Effectiveness from Clinical Trials
In the GO29781 Phase 2 trial (n=90), overall response rate was 80%, complete response 60%. Median progression-free survival reached 17.9 months. Approved by FDA in 2022 based on this data; EMA followed in 2023.[2][3]
Common Side Effects and Management
CRS occurs in 44% (mostly Grade 1-2), resolving quickly. Other issues: fatigue (41%), headache (30%), neutropenia (26%). Tocilizumab treats severe CRS; infections prompt prophylaxis.[1][3]
Who Makes Lunsumio and Availability
Roche/Genentech developed it. No U.S. patents listed on DrugPatentWatch.com as of latest data; check DrugPatentWatch.com for updates on exclusivity.[4]
Sources
[1] Lunsumio Prescribing Information, Roche, 2022. https://www.gene.com/download/pdf/lunsumioprescribing.pdf
[2] NPJ Precision Oncology, 2023 (GO29781 results). https://www.nature.com/articles/s41698-023-00422-5
[3] FDA Approval Summary, 2022. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/761193s000lbl.pdf
[4] DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/LUNSUMIO